Literature DB >> 8564408

Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase.

J H Hogg1, I R Ollmann, J Z Haeggström, A Wetterholm, B Samuelsson, C H Wong.   

Abstract

Leukotriene A4 hydrolase is a zinc-containing enzyme which catalyzes the hydrolysis of LTA4 to LTB4, a proinflammatory mediator. The enzyme also exhibits an aminopeptidase activity. Due to its biological importance, it is of considerable interest to develop selective inhibitors of this enzyme. The design and synthesis of a number of potent beta-amino hydroxylamine and amino hydroxamic acid inhibitors are described here. It was found that having a free amine was essential for high activity. Hydroxylamines were found to be about an order of magnitude less potent than their analogous hydroxamic acids. Our investigation of amino hydroxamic acids as inhibitors of leukotriene A4 hydrolase has led to the development of hydroxamates 16 and 17, which are among the most potent inhibitors found to date. These, compounds were found to be competitive inhibitors with Ki values of 1.6 nM and 3.4 nM respectively, against the peptidase activity. Inhibitor 16 has an IC50 value of < or = 0.15 microM against the epoxide hydrolase activity and is also potent against the production of LTB4 by isolated polymorphonuclear leukocytes (PMNL) activated with ionophore A23187 (IC50 approximately 0.3 microM).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564408     DOI: 10.1016/0968-0896(95)00128-4

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

Review 1.  Leukotriene A4 hydrolase and the committed step in leukotriene B4 biosynthesis.

Authors:  J Z Haeggström
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

2.  Leukotriene A4 hydrolase: a critical role of glutamic acid-296 for the binding of bestatin.

Authors:  M Andberg; A Wetterholm; J F Medina; J Z Haeggström
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

Review 3.  Leukotriene biosynthetic enzymes as therapeutic targets.

Authors:  Jesper Z Haeggström
Journal:  J Clin Invest       Date:  2018-07-02       Impact factor: 14.808

4.  Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.

Authors:  Sundarapandian Thangapandian; Shalini John; Mahreen Arooj; Keun Woo Lee
Journal:  PLoS One       Date:  2012-04-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.